ArticleJournal of molecular histology2025
Investigation of survivin and autophagy marker expression in different Indian cancer tissue samples.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Survivin, an inhibitor of apoptosis protein, is minimally expressed in normal adult tissues but overexpressed in multiple cancers. This study investigates survivin expression alongside autophagy markers ATG7 and LC3B in seven solid tumor types in Indian patient samples. Immunohistochemical analysis was performed on 48 cancer tissue samples (breast n = 7, buccal n = 6, cervical n = 5, colon n = 8, renal n = 6, liver n = 10, thyroid n = 6) and adjacent normal tissues (n = 9) using anti-human antibodies against survivin, ATG7, and LC3B. Expression levels were semi-quantitatively scored (0-3 +) and statistically analyzed. Survivin demonstrated significant overexpression in cancer tissues compared to normal tissues across all tumor types (p ≤ 0.05-0.0001). Moreover, a statistically significant inverse correlation was observed between survivin and autophagy marker (ATG7/LC3B) expression in 85% of examined samples. Breast, buccal, liver, and kidney cancers showed strong-to-moderate survivin expression in > 50% of cases, while thyroid cancers exhibited predominantly weak survivin expression with strong autophagy marker expression. These findings demonstrate consistent survivin overexpression with concomitant autophagy suppression in Indian cancer patients. The inverse relationship between survivin and autophagy marker expression suggests survivin inhibition as a potential therapeutic strategy to activate autophagic cell death, particularly in breast, buccal, liver, and kidney cancers with high survivin expression. Future large-scale validation studies and mechanistic investigations are warranted to translate these findings into personalized survivin-targeted therapeutic strategies. This study contributes to a better understanding of survivin and its relation to autophagy in various solid tumors, paving the way for novel therapeutics for cancer.
Indexed as
Identifiers
40921963What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.